Videos

In a poster presented at APA, researchers review current clinical practice guidelines for schizophrenia.

Allen Ho, MD, discusses the Protocol W outcomes and what they indicate for prescribing ophthalmologists.

Cardiology experts discuss challenges in achieving the optimal therapy for patients with heart failure and the influence of patient lifestyle and medical factors.

Insights on approaching the initiation of SGLT2 inhibitors for the treatment of heart failure with reduced ejection fraction.

Marla Dubinsky, MD, discusses what needs to be done to improve care for children with ulcerative colitis.

Researchers recently completed a 16-week phase 2b trial for patients with ulcerative colitis.

Marla Dubinsky, MD, discusses what adding adalimumab to the pediatric ulcerative colitis toolbox means for treatment strategies.

Abdullah Kutlar, MD, reviews the benefits and risks of treating patients with hemopoietic stem cell transplant.  

Experts discuss the considerations, as well as a specific case in patients receiving hemopoietic stem cell transplant (HSCT).

Joe Avelino, RN, BSN, MHSA, CPHQ, describes the patient care protocols upon discharge from the inpatient setting to the outpatient setting to assure that patients will continue their care.

Experts in the field of psychiatry discuss the differences between other specialties and psychiatry as well as the inconsistency within psychiatry itself.

David I. Bernstein, MD of the University of Cincinnati College of Medicine discusses the recent approval of short ragweed pollen allergen extract tablet (RAGWITEK) for the treatment of children and adolescents.

Charles Argoff, MD, leads a discussion on the use of pain contracts versus pain agreements between clinicians and patients to bring about desired outcomes.

Experts discuss the need for and impact of peer-to-peer discussion initiatives, as well as the impact telemedicine utilization has had on the opioid crisis.

Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.

Esther Freeman, MD, PhD, discusses the most frequent cutaneous presentations associated with vaccination.

An overview of standard treatment approaches approved to treat inflammatory bowel disease and recommendations for appropriately selecting therapy based on the disease’s clinical presentation.

Important factors to consider when classifying patients’ risk status during the diagnosis of an inflammatory bowel disease and the impact of risk assessment as it relates to treatment selection based on the current therapeutic algorithm.

Norman Lepor, MD, FACC, FAHA, FSCAI, challenges the use of ezetimibe before a PCSK9 inhibitor in a population with no acute coronary syndrome.

Key opinion leaders in cardiology share their perspectives on using inclisiran post FDA approval within the current treatment landscape based on guidelines.

A discussion on ease of access for dupilumab for the treatment of atopic dermatitis including the process for approval and coverage.

Examining the potential role for biologic, dupilumab, in the treatment of moderate to severe atopic dermatitis.

The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.

Seemal Desai, MD, gives an overview of the most promising research and therapies for patient of color populations.

Lawrence Eichenfield, MD, discusses future prescribing plans and safety assessment for the topical JAK 1/2 inhbitor.

The investigative topical cream benefits adolescent and adult skin clearance and itch. A study author discusses keeping it available to patients if it reaches the market.

A pair of AAD VMX studies show long-term repigmentization is possible with the JAK inhibitor. An expert explains why the drug could make history.

Brett King, MD, PhD, discusses new ground that that oral JAK inhibitor breaks in the alopecia areata therapeutic field.

Esther Freeman, MD, PhD, talks about the various levels of dermatologic severity associated with COVID-19.

Javed Butler, MD, MPH, MBA, reviews the historical background of using SGLT2 inhibitors and the impact on patients with heart failure with reduced ejection fraction.